» Articles » PMID: 36386987

Risk-to-befit Ratios of Consecutive Antidepressants for Heavy Menstrual Bleeding in Young Women with Bipolar Disorder or Major Depressive Disorder

Overview
Specialty Psychiatry
Date 2022 Nov 17
PMID 36386987
Authors
Affiliations
Soon will be listed here.
Abstract

The occurrence of heavy menstrual bleeding (HMB) induced by pharmacological agents has been reported in young adult women. This study aimed to investigate a possible association between the occurrence rates of HMB and different treatment methods such as antidepressant agents alone and in combination with other pharmacological agents. The examined cohort included young women (age 18-35 years, = 1,949) with bipolar disorder (BP) or major depressive disorder (MDD). Menstruation history for 24 months was recorded and evaluated according to pictorial blood loss assessment charts of HMB. Multivariate analyses were conducted to determine odds ratios (ORs) and 95% confidence intervals. The examined antidepressant agents had varying ORs for patients with BP vs. those with MDD. For example, the ORs of venlafaxine-induced HMB were 5.27 and 4.58 for patients with BP and MDD, respectively; duloxetine-induced HMB, 4.72 and 3.98; mirtazapine-induced HMB, 3.26 and 2.39; fluvoxamine-induced HMB, 3.11 and 2.08; fluoxetine-induced HMB, 2.45 and 1.13; citalopram-induced HMB, 2.03 and 1.25; escitalopram-induced HMB, 1.85 and 1.99; agomelatine-induced HMB, 1.45 and 2.97; paroxetine-induced HMB, 1.19 and 1.75; sertraline-induced HMB, 0.88 and 1.13; reboxetine-induced HMB, 0.45 and 0.45; and bupropion-induced HMB, 0.33 and 0.37, in each case. However, when antidepressant agents were combined with valproate, the OR of HMB greatly increased, with distinct profiles observed for patients with BP vs. those with MDD. For example, the ORs of HMB induced by venlafaxine combined with valproate were 8.48 and 6.70 for patients with BP and MDD, respectively; for duloxetine, 5.40 and 4.40; mirtazapine, 5.67 and 3.73; fluvoxamine, 5.27 and 3.37; fluoxetine, 3.69 and 4.30; citalopram, 5.88 and 3.46; escitalopram, 6.00 and 7.55; agomelatine, 4.26 and 5.65; paroxetine, 5.24 and 3.25; sertraline, 4.97 and 5.11; reboxetine, 3.54 and 2.19; and bupropion, 4.85 and 3.46, in each case. In conclusion, some antidepressant agents exhibited potential risks of inducing HMB. Therefore, a combined prescription of antidepressant agents and valproate should be carefully considered for young women with HMB.

References
1.
Kumar A, Datta S, Wright S, Furtado V, Russell P . Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev. 2013; (10):CD009582. PMC: 11339588. DOI: 10.1002/14651858.CD009582.pub2. View

2.
Reavey J, Walker C, Murray A, Brito-Mutunayagam S, Sweeney S, Nicol M . Obesity is associated with heavy menstruation that may be due to delayed endometrial repair. J Endocrinol. 2021; 249(2):71-82. PMC: 8052524. DOI: 10.1530/JOE-20-0446. View

3.
Ko J, Lao T, Cheung V . Pictorial Blood Loss Assessment Chart for evaluating heavy menstrual bleeding in Asian women. Hong Kong Med J. 2021; 27(6):399-404. DOI: 10.12809/hkmj208743. View

4.
Sole B, Jimenez E, Torrent C, Reinares M, Bonnin C, Torres I . Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. Int J Neuropsychopharmacol. 2017; 20(8):670-680. PMC: 5570032. DOI: 10.1093/ijnp/pyx032. View

5.
Boricevic Marsanic V, Kusmic E . Menorrhagia and ecchymoses in an adolescent girl treated with sertaline. Arch Womens Ment Health. 2010; 13(5):453-4. DOI: 10.1007/s00737-010-0171-5. View